Patents by Inventor Yasuhiro Funahashi

Yasuhiro Funahashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220117933
    Abstract: A combined administration of a liposomal composition comprising Eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist exhibits unexpected antitumor effect.
    Type: Application
    Filed: December 28, 2021
    Publication date: April 21, 2022
    Applicants: Eisai R&D Management Co., Ltd., Ono Pharmaceutical Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi, Takuya Suzuki
  • Publication number: 20210349097
    Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is responsive to a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.
    Type: Application
    Filed: October 2, 2019
    Publication date: November 11, 2021
    Inventors: Yasuhiro Funahashi, Yukinori Minoshima, Michio Kanekiyo, Masahiro Matsuki, Yusuke Adachi, Kotaro Kodama
  • Publication number: 20210333281
    Abstract: Biomarkers are provided that predict whether a subject having a hepatocellular carcinoma is responsive to a therapy comprising soratenib or a pharmaceutically acceptable salt thereof. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a hepatocellular carcinoma.
    Type: Application
    Filed: October 2, 2019
    Publication date: October 28, 2021
    Inventors: Yasuhiro Funahashi, Yukinori Minoshima, Michio Kanekiyo, Saori Miyano, Taisuke Hoshi
  • Patent number: 11083705
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: August 10, 2021
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Publication number: 20210177802
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof.
    Type: Application
    Filed: February 19, 2021
    Publication date: June 17, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Publication number: 20210123919
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a combination therapy comprising lenvatinib compound and a PD-1 antagonist. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having, suspected of having, or at risk of developing cancer.
    Type: Application
    Filed: May 13, 2019
    Publication date: April 29, 2021
    Applicants: Merck Sharp & Dohme Corp., Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro FUNAHASHI, Kotaro KODAMA, Ryo DAIRIKI, Yukinori MINOSHIMA
  • Patent number: 10945990
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: March 16, 2021
    Assignees: EISAI R&D MANAGEMENT CO., LTD., MERCK SHARP & DOHME CORP.
    Inventors: Junji Matsui, Gursel Aktan, Vassiliki Karantza, RuiRong Yuan, Yasuhiro Funahashi, Erhan Berrak
  • Publication number: 20210023047
    Abstract: Disclosed herein is a method for treating tumor, comprising administering a liposomal composition comprising eribulin or a pharmaceutically acceptable salt thereof and a PD-1 antagonist to a patient in need thereof
    Type: Application
    Filed: March 31, 2020
    Publication date: January 28, 2021
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yasuhiro Funahashi
  • Publication number: 20200199689
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 25, 2020
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Patent number: 10517861
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Grant
    Filed: May 12, 2014
    Date of Patent: December 31, 2019
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • Publication number: 20180209980
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 26, 2018
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20180136216
    Abstract: Biomarkers are provided that predict whether a human subject having a renal cell carcinoma is in need of a combination therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate) and everolimus. The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing a renal cell carcinoma.
    Type: Application
    Filed: May 27, 2016
    Publication date: May 17, 2018
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki
  • Patent number: 9945862
    Abstract: Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.
    Type: Grant
    Filed: May 31, 2012
    Date of Patent: April 17, 2018
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Junji Matsui, Jason S. Simon, Lucy Xu
  • Publication number: 20180071247
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and eribulin or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: March 3, 2016
    Publication date: March 15, 2018
    Applicants: MERCK SHARP & DOHME CORP., Eisai R&D Management Co., Ltd.
    Inventors: Junji MATSUI, Gursel AKTAN, Vassiliki KARANTZA, RuiRong YUAN, Yasuhiro FUNAHASHI, Erhan BERRAK
  • Publication number: 20170191137
    Abstract: The purpose of the present invention is to provide a method for predicting the effectiveness of an angiogenesis inhibitor in a subject suffering from a tumor. Provided is a method comprising a step of testing for the presence or absence of an a mutation or loss of expression of B-Raf and PTEN in a sample of tumor tissue from the subject. By using the presence or absence of or a mutation or loss of expression of B-Raf and PTEN as an indicator, this method enables the antitumor effectiveness of the angiogenesis inhibitor to be predicted without administering the angiogenesis inhibitor to the subject.
    Type: Application
    Filed: March 16, 2017
    Publication date: July 6, 2017
    Applicant: Eisai R&D Management Co., Ltd.
    Inventors: Taro Semba, Yusuke Narita, Yukinori Minoshima, Atsumi Yamaguchi, Yusuke Adachi, Kazuhiko Yamada, Junji Matsui, Tadashi Kadowaki, Kentaro Takahashi, Yasuhiro Funahashi
  • Publication number: 20170071903
    Abstract: Methods for treating cancer (e.g., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovarian cancer, endometrial cancer, pharyngeal cancer, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g., eribulin mesylate, i.e., E7389, Halaven) in combination with one or more mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus, ridaforolimus, and temsirolimus), and kits therefor are provided.
    Type: Application
    Filed: March 2, 2015
    Publication date: March 16, 2017
    Inventors: Yasuhiro FUNAHASHI, Bruce A. Littlefield, Toshimitsu UENAKA
  • Publication number: 20160089366
    Abstract: Biomarkers are provided that predict whether a subject having endometrial cancer will or will not respond to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for and treating a subject having, suspected of having, or at risk of developing an endometrial cancer.
    Type: Application
    Filed: May 12, 2014
    Publication date: March 31, 2016
    Inventors: Yasuhiro Funahashi, Tadashi Kadowaki, Pallavi Sachdev
  • Publication number: 20150329615
    Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.
    Type: Application
    Filed: March 25, 2015
    Publication date: November 19, 2015
    Applicant: The Trustees of Columbia University in the City of New York
    Inventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi
  • Patent number: 9012458
    Abstract: An antitumor agent for combined use of a compound or pharmaceutically acceptable salt thereof represented by Formula (I) and a compound or pharmaceutically acceptable salt thereof represented by Formula (II) exhibits an excellent antitumor effect compared to cases where these are individually used, and exhibits antitumor effects against various cancer types: wherein R1 is azetidinyl and the like, R2 to R5 is a hydrogen atom or a halogen atom, R6 is C3-8 cycloalkyl and the like, R7 is a hydrogen atom and the like, and R8 is a halogen atom and the like.
    Type: Grant
    Filed: June 23, 2011
    Date of Patent: April 21, 2015
    Assignee: Eisai R&D Management Co., Ltd.
    Inventors: Takayuki Nakagawa, Tomohiro Matsushima, Yasuhiro Funahashi
  • Patent number: 8993725
    Abstract: This invention provides a method for treating a subject having a tumor and a method for inhibiting angiogenesis in a subject, both comprising administering to the subject an effective amount of a composition of matter comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety. This invention also provides a composition of matter comprising the extracellular domain of Notch4 receptor protein operably affixed to a half-life-increasing moiety. This invention further provides an article of manufacture. Finally, this invention provides a replicable vector which encodes a polypeptide comprising the extracellular domain of a Notch receptor protein operably affixed to a half-life-increasing moiety, a host vector system which comprises such replicable vector and a method of producing such polypeptide.
    Type: Grant
    Filed: January 21, 2010
    Date of Patent: March 31, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Jan Kitajewski, Carrie Shawber, Yasuhiro Funahashi